"label","uuid:ID","id","description","rationale","name"
"","b1442534-255e-4844-b0ce-bd9276205f9e","StudyDesign_1","The main design for the study","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","Study Design 1"
